PHARMANOVIA STRENGTHENS MEDICAL AFFAIRS TEAM WITH KEY APPOINTMENTS TO SUPPORT GLOBAL GROWTH

PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY

PHARMANOVIA STRENGTHENS MEDICAL AFFAIRS TEAM WITH KEY APPOINTMENTS TO SUPPORT GLOBAL GROWTH

• Pharmanovia has made five key appointments to its medical affairs function
• The expansion of the function, led by Associate Vice President (AVP), Medical Affairs, Fernando Osorio reflects Pharmanovia's rapid growth trajectory and its commitment to advancing global patient care

BASILDON, UK, 30 NOVEMBER 2023

Pharmanovia, a global pharmaceutical company that repurposes and expands the lifecycle of novel and established medicines using value added approaches, has today confirmed the expansion of its medical affairs function. The new appointments will support the delivery of the company’s ambitious growth trajectory and underpin Pharmanovia’s commitment to bolstering its medical engagement activities.

The following key appointments have been announced:

• Dr Anissa Korichi will take on the role of Cardiology Medical Lead, overseeing all cardiovascular portfolio strategies. Anissa has over 15 years industry experience, serving as the Scientific Director of Vifor Pharma prior to joining Pharmanovia. Anissa has also gained expertise within multiple therapy areas, namely oncology and cardiovascular disease, in several different pharmaceutical companies including Roche, Novartis and BMS.
• Winnie Ndoro joins as the new Senior Manager, Medical Information. Winnie leads this critical function, ensuring rigorous oversight of medical information. Winne brings with her a wealth of experience, with over 15 years spanning medical information, international review and scientific affairs for numerous biotech and pharmaceutical organisations.
• Dr August Wong joins as Director of Medical Affairs, based in China. With a profound background within the scientific and medical space, August will specialise as Endocrinology Medical Lead, advancing the bone disorder element of this therapeutic area. Prior to joining Pharmanovia, August was a central member of the MSD Medical Affairs team for 10 years, as therapeutic lead for Endocrinology & Women’s health.
• Dr Eric Wang joins Pharmanovia as Senior Manager, Medical Science Liaison (MSL). Eric will serve as the APAC regional expert for osteoporosis, leading the company’s engagements with key partners within this sub-therapeutic area of Endocrinology. Eric brings over 16 years’ experience; with valuable clinical expertise gained during his eight-year service as a breast surgeon and almost a decade’s worth of experience as an MSL.
• Nadja Scheuringer joins as MSL for Germany, Austria and Switzerland respectively. Nadja brings a breadth of industrial proficiency, previously holding MSL roles in the field of neurology, pneumonology and gastroenterology.

Working under the stewardship of AVP, Medical Affairs, Fernando Osorio, within the broader Scientific Affairs function, the new hires will continue to enhance the company’s medical engagement initiatives aimed at addressing the unmet needs across Pharmanovia’s four therapeutic focus areas.

Stephen Deacon, Chief Scientific Officer, Pharmanovia, shared his enthusiasm on the appointments: “I am delighted to announce the addition of these experienced professionals to our team.

“Medical Affairs is an essential function, pivotal in how we shape innovation and address unmet need across our portfolio. We are committed to establishing a best-in-class Medical Affairs team, which can identify and engage with global, regional, and local experts to gain insights that will be crucial in helping us create new ways to make today’s medicines relevant for tomorrow. “

-Ends-

Notes to editors

For further information, please contact:

Alison Dyson, Director of Communications, Pharmanovia

07442 256310/ communications@pharmanovia.com

Or pharmanovia@67health.co.uk

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.